Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling

The newest addition to the Illumina oncology portfolio offers researchers the ability to measure Tumor Mutational Burden and Microsatellite Instability, and detect other known and emerging biomarkers

SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2018-- Illumina, Inc. (NASDAQ: ILMN) today announces the launch of TruSight^TM Oncology 500 (TSO 500), a comprehensive pan-cancer assay designed to identify known and emerging tumor biomarkers. TruSight Oncology 500 utilizes both DNA and RNA from subject tumor samples to identify key somatic variants underlying tumor progression, such as small DNA variants, fusions, and splice variants. Importantly, TruSight Oncology 500 can measure tumor mutational burden (TMB) and microsatellite instability (MSI), features that are potentially key biomarkers for emerging immunotherapies. TruSight Oncology 500 is for research use only and will ship in Q1 2019.

Molecular testing in lung cancer has been at the forefront of precision oncology. The use of targeted therapies is associated with improved outcomes in some patients, and currently requires testing multiple biomarkers, such as EGFR mutations, ALK fusions, and ROS fusions, among others. Recently, TMB gained prominence as a biomarker that demonstrates better response and survival from immune checkpoint inhibitors in patients exhibiting high TMB, necessitating the need for comprehensive sequencing. Reliable measurement of TMB in a tumor-only workflow requires sequencing of approximately 1Mb or greater, specific and sensitive variant calling, as well as bioinformatic methods to flag and remove germline variants. Given the increasing number of biomarkers required to fully understand the optimal therapeutic course, assays like TruSight Oncology 500—one of the largest and most comprehensive panels to-date—encompasses all of these biomarkers, making it an ideal choice for cancer researchers today.

“The importance of tumor mutational burden as a biomarker to predict immune checkpoint inhibition response continues to grow in non-small cell lung cancer,” said Albrecht Stenzinger, MD, pathologist at University Hospital Heidelberg, Germany. “However, the detection of somatic biomarkers, such as ALK fusions and EGFR small variants, are also vital. The workflow of TSO 500, using both DNA and RNA, enables laboratories to evaluate TMB, as well as small DNA variants and fusions simultaneously, ultimately saving time and preserving precious samples.”

“While many methods are arising that measure TMB, these methods may differ in their variant calling performance and their gene content, affecting measurement,” said Dr. Carina Heydt, a molecular biologist at the University of Cologne, Institute of Pathology, in Germany. “As an early access site for TSO 500, not only did we find the assay easy to implement in our laboratory, but the enrichment-based chemistry of the assay, coupled with the novel bioinformatic pipeline, demonstrate a high-variant calling performance and reproducible TMB measurements.”

Pharmaceutical partners and payers are shifting toward deeper, broader sequencing to help predict which patients may benefit from new treatments including immunotherapies, targeted therapies and the many potential combinations. Recently, Bristol-Myers Squibb Company (NYSE: BMY) and Illumina announced a collaboration to develop and globally commercialize companion diagnostics, based on TruSight Oncology 500 content, to support Bristol-Myers Squibb’s oncology portfolio.

“By focusing on our most differentiated oncology products, we can meet the needs of our customers and provide a comprehensive NGS panel that includes all of the known and anticipated biomarkers associated with targeted and immune-based therapies,” said Garret Hampton, Executive Vice President of Clinical Genomics at Illumina. “As we move to bring a future in vitro diagnostic version through regulatory approval, we will be able to set the standard for accurate and reproducible testing. Today’s value in the capability to call for TMB is in line with current research and emerging guidelines, but the promise that TruSight Oncology 500 holds for the future identification of biomarkers, makes it a robust solution for this rapidly evolving field.”

TruSight Oncology 500 offers deep, adaptable, and accessible sequencing power:

• Goes beyond current cancer guidelines and clinical trials – The deep investigational power of TSO 500 covers a large number of genes – alterations that are being used to identify patients for clinical trials – while covering 1.94Mb of the genome to measure TMB.
• Unlocks immunotherapy research – Rigorously developed and accurate TMB and MSI algorithms, with a dedicated tumor-only workflow, while also offering the flexibility to detect a vast majority of known genetic variants, whether it be small variants, gene amplifications, de novo fusions, or splice variants.
• Integrated tumor-only, RNA+DNA workflow: The ability to run RNA and DNA biomarkers into one workflow enables a lab to evaluate all relevant biomarkers at the same time. In addition, being able to run tumor-only workflow enables cost savings for a lab since there is no need to run a normal sample each time.

For additional product and availability information, please visit: www.illumina.com/TruSightOncology500

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statement This release contains projections, information about our financial outlook, earnings guidance, and other forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables and to deploy new products, including diagnostic assays, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation, consumables, including diagnostic assays; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; (v) challenges inherent in developing, manufacturing, and launching new products and services; (vi) our ability to obtain necessary regulatory approvals to market and sell diagnostic or therapeutic products and (vii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181030006045/en/

Source: Illumina, Inc.

Illumina, Inc.
Media Contacts
Lisa Warshaw
(858) 882-6822
pr@illumina.com
or
Investors:
Jacquie Ross, CFA
(858) 882-2172
ir@illumina.com